Cerebrospinal Fluid Management Devices Market Share

Global Cerebrospinal Fluid Management Devices Market Overview

Cerebrospinal Fluid Management Devices Market Size was valued at USD 1.15 Billion in 2023. The cerebrospinal fluid management devices market industry is anticipated to grow from USD 1.20 Billion in 2024 to USD 1.69 Billion by 2032, exhibiting a compound annual growth rate (CAGR) between 2024 and 2032 of about 4.30%. The prevalence of neurological disorders, the aging population, the high demand for minimally invasive surgeries, the growth of the healthcare infrastructure, the development of cutting-edge devices, and rising disposable incomes are the key market drivers fostering the growth of the market. Hospitals are treating numerous neurovascular illnesses due to new product introductions and technological improvements, creating more fruitful market expansion prospects throughout the projection period.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

The brain's ventricles are filled with cerebrospinal fluid, an ultrafiltrate of plasma that nourishes, cleanses, and protects the brain. The disease known as hydrocephalus can develop when there is an excess of cerebrospinal fluid that accumulates within the brain's ventricles or cavities that contain fluid. The estimated adult CSF volume is 150 ml, with 125 ml distributed in the subarachnoid areas and 25 ml in the ventricles. The extra CSF surrounding the brain can put dangerous pressures on the parts of the brain enclosed in the skull. The market for cerebrospinal fluid (CSF) management is expected to rise at a high rate during the forecast period due to an increase in the number of shunting procedures and the prevalence of hydrocephalus.

The aging population is more susceptible to specific diseases like Alzheimer's and Parkinson's, growing awareness of minimally invasive surgery, rising stroke and hydrocephalus cases, and technological advancements contribute to the market's overall growth. However, the market's growth is constrained by the simple accessibility of alternative treatments and the constrained hospital budget. CSF can build up because of increased fluid production, decreased absorption rate, or a disease that prevents fluid from flowing normally through the ventricular system. The high potential for technology adoption in emerging nations due to the rising prevalence of CSF-related illnesses, expansion of the market, and surge in demand for CSF management is also anticipated to fuel the projected expansion of the cerebral spinal fluid management market. Additionally, the demand for better healthcare technologies, significant government investments in the sector, and the establishment of robust medical device sectors in emerging economies all contribute to the significant growth of the healthcare sector in emerging economies.

Anuncia Medical Inc. has announced the FDA-cleared ReFlow Mini Flusher device's first successful implant. The company specializes in advancing solutions for implanted and external cerebrospinal fluid (CSF) management systems, including neurocritical care. The second-generation, FDA-approved ReFlow Mini Flusher is recommended for people with hydrocephalus or comparable diseases. The technology's smaller size and lower profile are intended to support a wider range of hydrocephalus patients, from young children to senior adults. With just a simple fingertip depression of the flusher's soft dome placed beneath the patient's head, the ReFlow Mini Flusher has been developed to flush the individual's CSF back into the ventricular catheter to sustain, repair, or improve hydrocephalus shunt flow in line with any shunt system brand.

Cerebrospinal Fluid Management Devices Market Trends

• Rising brain injuries are driving the market growth

Market CAGR for cerebrospinal fluid management devices is driven by the rising number of brain injuries. Shunts, which are CSF devices used to drain any cerebrospinal fluid built around the brain, are important in treating traumatic brain injury (TBI). Traumatic brain injury (TBI) affects between 1.5 and 2 million adults and children annually in the United States, making it one of the major causes of mortality. Of the 1.1 million people at risk for head injuries, 235,000 will require hospitalization for moderate to severe brain trauma, and almost 50,000 will die. The bulk of them will have minor wounds that won't necessitate hospitalization. The market for cerebrospinal fluid management devices will expand due to increased brain injuries.

 Developing countries offer commercial opportunities because of their underdeveloped research and development sectors and inability to manage new health issues. Despite their strong need, Africa depends on imported medicines and other medical supplies. Even though Africa has a lot of medical requirements, the continent's weak economic conditions are causing the healthcare industry to grow slowly. Furthermore, developing nations like Brazil, Russia, and China have sizable patient populations for neurological diseases. The large patient base in this region and the rising healthcare expense would open up chances for market participants for cerebrospinal fluid management devices. Thus, driving the cerebrospinal fluid management devices market revenue.

Cerebrospinal Fluid Management Devices Market Segment Insights

The cerebrospinal fluid management devices market segmentation, based on device type, includes rubber band ligators, infrared coagulators, proctoscopes, anoscopes, doppler probes, cryotherapy devices, bipolar probes, and others. In 2022, the cryotherapy devices sector dominated the market. The primary factors affecting the market's growth are the increased prevalence of cancer and sports injuries, the rising desire for minimally invasive therapies, and technological advancements in cryotherapy devices.

October 2022: Channel Medsystems, Inc. revealed that the Cerene Cryotherapy Device was used for the first time in Europe to treat heavy menstrual bleeding (HMB). Fleur Bergwerff, M.D., performed the treatments at Bergman Clinics in Amsterdam, the Netherlands' largest network of clinics providing outpatient care and procedures to targeted medical specialists and their patients.

Additionally, in 2022, the Doppler probes sector witnessed the fastest growth rate. The segment for Doppler probes is expanding due to increased knowledge of less invasive diagnostic techniques, an increase in the prevalence of chronic diseases, and improvements in medical technology.

Cerebrospinal Fluid Management Devices Procedure Insights

The cerebrospinal fluid management devices market segmentation, based on procedure, includes rubber band ligation, sclerotherapy, infrared coagulation, and others. The sclerotherapy segment dominated the market, accounting for 52.9% of market revenue (0.6 Billion). Globally increasing rates of varicose veins and thrombotic disorders that result in stroke or mesenteric ischemia are expected to fuel market growth. The rubber band ligation segment experienced the fastest growth rate in 2022. The device sector is driven by a considerable increase in the prevalence of disorders linked to aging and a growth in the need for endoscopic operations requiring ligation devices.

Figure 1: Cerebrospinal Fluid Management Devices Market, by Procedure, 2022 & 2032 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Cerebrospinal Fluid Management Devices End-User Insights

The cerebrospinal fluid management devices market segmentation, based on end-user, includes hospitals & clinics, ambulatory surgery centers, and others. The hospitals & clinics sector dominated the market in 2022. Cerebrospinal fluid management devices are gaining popularity among neurosurgeons due to their ease of use, low cost, outstanding safety, and efficiency. Increased patient traffic to general and specialized neurological institutions benefits hospitals. Due to growing academic institute cooperation and an increase in international research on diagnosing and treating neurological disorders, including hydrocephalus, ambulatory surgery centers are anticipated to expand during the projected period.

News:

To develop Alcyone's ThecaFlex DRxTM System, an implantable medical device targeted for subcutaneous injection of antisense oligonucleotide (ASO) therapeutics into the intrathecal space, Biogen Inc. & Alcyone Therapeutics (Alcyone) are entering into a license and partnership agreement. With the help of this agreement, Biogen hopes to make better use of the ThecaFlex DRxTM System and increase patient accessibility for a larger group of people dealing with neurological conditions like spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).

Cerebrospinal Fluid Management Devices Regional Insights

By region, the report gives market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American cerebrospinal fluid management devices market area will dominate this market due to the region's large number of medical device manufacturers, booming healthcare industry, and high acceptance rate among medical experts. Numerous small and medium-sized enterprises have actively joined this market by trying to develop shunts and valves to treat hydrocephalus.

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

Figure 2: CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET SHARE BY REGION 2022 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Europe’s cerebrospinal fluid management devices market accounts for the second-largest market share. Leading manufacturers, the rise of the biopharmaceutical industry, government support of R&D, a high level of disposable income, and the accessibility of cutting-edge technology are key factors influencing the market's expansion. Some market participants build partnerships with vascular and neurosurgeons to get a competitive edge. Further, the German cerebrospinal fluid management devices market held the major market share, and the UK cerebrospinal fluid management devices market was the rapidly growing market in the European region.

The Asia-Pacific Cerebrospinal Fluid Management Devices Market is expected to grow at a rapid rate from 2023 to 2032. The market's expansion is significantly influenced by rising healthcare spending, research, public awareness of well-known businesses, and funding for that research. Moreover, China’s cerebrospinal fluid management devices market held the largest market share, and the Indian cerebrospinal fluid management devices market was the rapidly growing market in the Asia-Pacific region.

Cerebrospinal Fluid Management Devices Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the cerebrospinal fluid management devices market, grow even more. To increase their worldwide footprint, market participants are also engaging in various strategic actions. Important market developments include introducing new products, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the cerebrospinal fluid management devices industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the cerebrospinal fluid management devices industry to benefit clients and increase the market sector. In recent years, the cerebrospinal fluid management devices industry has offered some of the most significant medical advantages. Major players in the cerebrospinal fluid management devices market, including Argi Grup (Turkey), Integra Lifesciences Corporation (US), Möller Medical GmbH (Germany), Braun Melsungen AG (Germany), Medtronic Plc (Ireland), and others, are attempting to increase market demand by investing in research and development operations.

CereVasc is a medical device firm that treats individuals with neurological illnesses. The company's solutions include an endovascularly implantable CSF shunt and associated delivery components that eliminate the need for invasive surgery, general anesthesia, prolonged hospitalization, and post-procedure pain treatment. In December 2021, CereVasc introduced the eShunt as the first minimally invasive cerebrospinal fluid shunt. It attempts to eliminate the need for invasive surgery and protracted hospitalization currently associated with the surgical treatment of hydrocephalus. Product introductions are expected to drive market expansion.

Aesculap is a surgical product manufacturer and distributor in Germany. Surgical sutures, navigation systems, and neurosurgical equipment ranging from general surgery to arthroscopy and orthopedics are among the company's surgical products, allowing medical companies to obtain a diverse range of technologically advanced equipment to execute complex surgeries. In May 2020, Aesculap, Inc. was thrilled to announce the debut of the M.blue valve, the next generation of Hydrocephalus valve technology, in collaboration with The Christoph Miethke GmbH & Co. KG (MIETHKE). Its one-of-a-kind gravitational technology is combined with a fixed differential pressure unit in a single valve, allowing for a straightforward, position-dependent solution.

Key Companies in the cerebrospinal fluid management devices market include

• 
  

  Medtronic Plc (Ireland)

  
  


• 
  

  Natus Medical Incorporated (US)

  
  


• 
  

  Braun Melsungen AG (Germany)

  
  


• 
  

  Sophia (France)

  
  


• 
  

  IRRAS AB (Sweden)

  
  


• 
  

  Möller Medical GmbH (Germany)

  
  


• 
  

  Argi Grup (Turkey)

  
  


• 
  

  Longeviti (US)

  
  


• 
  

  Integra Lifesciences Corporation (US)

  
  

Cerebrospinal Fluid Management Devices Industry Developments

January 2023: Biogen and Alcyone Therapeutics have agreed to a licensing and partnership agreement to develop an implantable medical device for intrathecal (IT) medication administration. ThecaFlex DRx, a system developed by Alcyone, is being created for the subcutaneous administration of therapeutic antisense oligonucleotides (ASOs) to the IT region. It is believed to be the first implanted device to allow routine subcutaneous injection of ASO treatments into the cerebrospinal fluid (CSF).

August 2021: National Institute of Neurological Disorders and Stroke has awarded USD 14 million to Johns Hopkins Cerebral Fluid Centre researchers in the Department of Neurosurgery. The study is being carried out in collaboration with the Adult Hydrocephalus Clinical Research Network (AHCRN) and coordinated by the Hydrocephalus Association, a non-profit organization dedicated to hydrocephalus research.

Cerebrospinal Fluid Management Devices Market Segmentation

Cerebrospinal Fluid Management Devices Type Outlook

• 
  

  Rubber Band Ligators

  
  


• 
  

  Infrared Coagulators

  
  


• 
  

  Proctoscopes

  
  


• 
  

  Anoscopes

  
  


• 
  

  Doppler probes

  
  


• 
  

  Cryotherapy Devices

  
  


• 
  

  Bipolar Probes

  
  


• 
  

  Others

  
  

Cerebrospinal Fluid Management Devices Procedure Outlook

• 
  

  Rubber Band Ligation

  
  


• 
  

  Sclerotherapy

  
  


• 
  

  Infrared Coagulation

  
  


• 
  

  Others

  
  

Cerebrospinal Fluid Management Devices End-User Outlook

• 
  

  Hospitals & Clinics

  
  


• 
  

  Ambulatory Surgery Centers

  
  


• 
  

  Others

  
  

Cerebrospinal Fluid Management Devices Regional Outlook

• 
  

  North America

  
  

• 
  
  
  
  • US
  
  
  • Canada
  
  
  
  

• 
  

  Europe

  
  

• 
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific

• 
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World

• 
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America